Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 933

1.

[People in view, brain in focus].

Hartung HP, Gold R.

Nervenarzt. 2015 Jul 26. [Epub ahead of print] German. No abstract available.

PMID:
26208545
2.

Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography.

Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller AK, Finis D, Guthoff R, Bergholz R, Duning T, Krämer M, Paul F, Brandt A, Oberwahrenbrock T, Mikolajczak J, Wildemann B, Jarius S, Hartung HP, Aktas O, Dörr J.

Neurology. 2015 Jul 22. pii: 10.1212/WNL.0000000000001852. [Epub ahead of print]

PMID:
26203089
3.

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20.

PMID:
26198921
4.

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

Winkelmann A, Löbermann M, Reisinger EC, Hartung HP, Zettl UK.

Nervenarzt. 2015 Jul 19. [Epub ahead of print] German.

PMID:
26187545
5.

[Immunotherapy and infectious issues in multiple sclerosis : Self-injectable and oral drugs for immunotherapy].

Winkelmann A, Löbermann M, Reisinger EC, Hartung HP, Zettl UK.

Nervenarzt. 2015 Jul 19. [Epub ahead of print] German.

PMID:
26187544
6.

Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography.

Albrecht P, Blasberg C, Lukas S, Ringelstein M, Müller AK, Harmel J, Kadas EM, Finis D, Guthoff R, Aktas O, Hartung HP, Paul F, Brandt AU, Berlit P, Methner A, Kraemer M.

Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001832. [Epub ahead of print]

PMID:
26180140
7.

Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke.

Gliem M, Krammes K, Liaw L, van Rooijen N, Hartung HP, Jander S.

Glia. 2015 Jul 7. doi: 10.1002/glia.22885. [Epub ahead of print]

PMID:
26148976
8.

[New therapeutic strategies for remyelination in multiple sclerosis].

Kremer D, Hartung HP, Stangel M, Küry P.

Nervenarzt. 2015 Jun 28. [Epub ahead of print] German.

PMID:
26122637
9.

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group.

J Neurol Neurosurg Psychiatry. 2015 Jun 25. pii: jnnp-2015-310597. doi: 10.1136/jnnp-2015-310597. [Epub ahead of print]

10.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

11.

Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth.

Tzekova N, Heinen A, Bunk S, Hermann C, Hartung HP, Reipert B, Küry P.

J Neuroinflammation. 2015 May 29;12:107. doi: 10.1186/s12974-015-0331-7.

12.

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.

Bayry J, Hartung HP, Kaveri SV.

Trends Pharmacol Sci. 2015 Jul;36(7):419-21. doi: 10.1016/j.tips.2015.04.012. Epub 2015 May 20.

PMID:
26003802
13.

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I.

JAMA Neurol. 2015 Jul 1;72(7):756-63. doi: 10.1001/jamaneurol.2015.0533.

PMID:
25985228
14.

Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype.

Heinen A, Beyer F, Tzekova N, Hartung HP, Küry P.

Exp Neurol. 2015 May 7;271:25-35. doi: 10.1016/j.expneurol.2015.05.002. [Epub ahead of print]

PMID:
25957629
15.

Dehydrated hereditary stomatocytosis masquerading as MDS.

Paessler M, Hartung H.

Blood. 2015 Mar 12;125(11):1841. No abstract available.

PMID:
25927085
16.

Pancytopenia in a patient with methylmalonic acidemia.

MacFarland S, Hartung H.

Blood. 2015 Mar 12;125(11):1840. No abstract available.

PMID:
25927084
17.

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group.

Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

PMID:
25876473
18.

Electrical stimulation alleviates depressive-like behaviors of rats: investigation of brain targets and potential mechanisms.

Lim LW, Prickaerts J, Huguet G, Kadar E, Hartung H, Sharp T, Temel Y.

Transl Psychiatry. 2015 Mar 31;5:e535. doi: 10.1038/tp.2015.24.

19.

Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia.

Babushok DV, Perdigones N, Perin JC, Olson TS, Ye W, Roth JJ, Lind C, Cattier C, Li Y, Hartung H, Paessler ME, Frank DM, Xie HM, Cross S, Cockroft JD, Podsakoff GM, Monos D, Biegel JA, Mason PJ, Bessler M.

Cancer Genet. 2015 Apr;208(4):115-28. doi: 10.1016/j.cancergen.2015.01.007. Epub 2015 Feb 2.

PMID:
25800665
20.

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755.

PMID:
25800129
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk